Carlos Costa

CIK: 0001939167

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (41.7%)

Position reduction

Option Exercises (M)5 (41.7%)

Derivative conversions

Awards (A)2 (16.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

FHTX

Foghorn Therapeutics Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

FHTX
Foghorn Therapeutics Inc.
Jan 30, 2026
Award(A)
Stock option (right to buy)
Direct
230K shares at avg. $5.71-
FHTX
Foghorn Therapeutics Inc.
Jan 22, 2025
Award(A)
Stock Option (right to buy)
Direct
115K shares at avg. $4.37-
FHTX
Foghorn Therapeutics Inc.
Sep 23, 2024
Exercise(M)
Direct
857 shares at avg. $3.72$3K
FHTX
Foghorn Therapeutics Inc.
Sep 23, 2024
Sale(S)
Direct
857 shares at avg. $10.17$9K
FHTX
Foghorn Therapeutics Inc.
Sep 20, 2024
Exercise(M)
Direct
35.8K shares at avg. $3.72$133K
FHTX
Foghorn Therapeutics Inc.
Sep 20, 2024
Sale(S)
Direct
35.8K shares at avg. $10.04$359K
FHTX
Foghorn Therapeutics Inc.
Sep 18, 2024
Sale(S)
Direct
11.6K shares at avg. $10.05$116K
FHTX
Foghorn Therapeutics Inc.
Sep 18, 2024
Exercise(M)
Direct
11.6K shares at avg. $3.72$43K
FHTX
Foghorn Therapeutics Inc.
Sep 17, 2024
Exercise(M)
Direct
10.3K shares at avg. $3.72$38K
FHTX
Foghorn Therapeutics Inc.
Sep 17, 2024
Sale(S)
Direct
10.3K shares at avg. $10.04$103K
FHTX
Foghorn Therapeutics Inc.
Sep 16, 2024
Exercise(M)
Direct
400 shares at avg. $3.72$1K
FHTX
Foghorn Therapeutics Inc.
Sep 16, 2024
Sale(S)
Direct
400 shares at avg. $10.00$4K

		Type	Shares	Price		Ownership
Jan 30, 2026	FHTX Foghorn Therapeutics Inc.	Award(A) Stock option (right to buy)	230,000	$5.71	-	Direct
Jan 22, 2025	FHTX Foghorn Therapeutics Inc.	Award(A) Stock Option (right to buy)	115,000	$4.37	-	Direct
Sep 23, 2024	FHTX Foghorn Therapeutics Inc.	Exercise(M)	857	$3.72	$3,188	Direct
Sep 23, 2024	FHTX Foghorn Therapeutics Inc.	Sale(S)	857	$10.17	$8,716	Direct
Sep 20, 2024	FHTX Foghorn Therapeutics Inc.	Exercise(M)	35,756	$3.72	$133,012	Direct
Sep 20, 2024	FHTX Foghorn Therapeutics Inc.	Sale(S)	35,756	$10.04	$358,990	Direct
Sep 18, 2024	FHTX Foghorn Therapeutics Inc.	Sale(S)	11,574	$10.05	$116,319	Direct
Sep 18, 2024	FHTX Foghorn Therapeutics Inc.	Exercise(M)	11,574	$3.72	$43,055	Direct
Sep 17, 2024	FHTX Foghorn Therapeutics Inc.	Exercise(M)	10,272	$3.72	$38,212	Direct
Sep 17, 2024	FHTX Foghorn Therapeutics Inc.	Sale(S)	10,272	$10.04	$103,131	Direct
Sep 16, 2024	FHTX Foghorn Therapeutics Inc.	Exercise(M)	400	$3.72	$1,488	Direct
Sep 16, 2024	FHTX Foghorn Therapeutics Inc.	Sale(S)	400	$10.00	$4,000	Direct

1-12 of 12 transactions

About Costa Carlos

Costa Carlos (SEC CIK 0001939167) files insider reports with the SEC as Chief People Officer of Foghorn Therapeutics Inc. (FHTX).

Signal8 holds 5 ownership filings by Costa Carlos, all Form 4s, filed between Sep 18, 2024 and Feb 2, 2026. Those filings report 12 transactions, from Sep 16, 2024 to Jan 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Costa Carlos's filings is in WATERTOWN, MA.

Recent filings by Costa Carlos

Jan 30, 2026: Grant or award of FHTX derivative securities (Form 4, code A).
Jan 22, 2025: Grant or award of FHTX derivative securities (Form 4, code A).
Sep 23, 2024: Option exercise of FHTX shares (Form 4, code M).
Sep 23, 2024: Open-market sale of FHTX shares (Form 4, code S).
Sep 20, 2024: Option exercise of FHTX shares (Form 4, code M).

Other insiders filing for Foghorn Therapeutics Inc. (FHTX)

BVF PARTNERS L P/IL, 10% Owner
Lynch Thomas J. Jr., Director
Duty Stuart, Director
Biller Scott, Director
Gallagher Neil, Director
Mendelsohn Michael, Director

How to read Form 4 transaction codes